Bulletin
Investor Alert

Moderna Inc.

NAS: MRNA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 10, 2021, 7:59 p.m.

/zigman2/quotes/205619834/composite

$

159.68

Change

+1.13 +0.71%

Volume

Volume 238,469

Quotes are delayed by 20 min

/zigman2/quotes/205619834/composite

Previous close

$ 163.15

$ 158.55

Change

-4.60 -2.82%

Day low

Day high

$155.71

$164.76

Open

52 week low

52 week high

$46.13

$189.26

Open

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Valuation

P/E Ratio (with extraordinary items)

117.28

Price to Sales Ratio

49.59

Price to Book Ratio

16.27

Price to Cash Flow Ratio

19.77

Enterprise Value to Sales

44.15

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

617,996.00

Income Per Employee

-574,665.00

Receivables Turnover

1.13

Total Asset Turnover

0.18

Liquidity

Current Ratio

1.43

Quick Ratio

1.42

Cash Ratio

1.05

Profitability

Gross Margin

95.12

Operating Margin

-94.99

Pretax Margin

-92.67

Net Margin

-92.99

Return on Assets

-16.74

Return on Equity

-39.99

Return on Total Capital

-37.14

Return on Invested Capital

-36.66

Capital Structure

Total Debt to Total Equity

9.28

Total Debt to Total Capital

8.49

Total Debt to Total Assets

3.24

Long-Term Debt to Equity

8.09

Long-Term Debt to Total Capital

7.41

Officers and Executives

Name Age Officer Since Title
Mr. Stéphane Bancel 47 2011 President, Founding CEO & Director
Dr. Stephen Hoge 43 2013 SVP-Corporate Development & New Drug Concepts
Mr. David W. Meline 62 2020 Chief Financial Officer
Mr. Juan Andres 54 2017 Chief Technical Operations & Quality Officer
Dr. Tal Zaks 54 2015 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/06/2021 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $147.82 per share. 1,478,200
05/06/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $147.82 per share. 975,612
05/06/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
05/05/2021 Stéphane Bancel
Chief Executive Officer; Director
2,000   Gift at $0 per share. 0
05/05/2021 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $178.34 per share. 1,605,060
05/05/2021 Juan Andres
See remarks
5,000   Disposition at $178.34 per share. 891,700
05/05/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
05/04/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $185.25 per share. 1,222,650
05/04/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
05/03/2021 Stephen Hoge
President
20,000   Disposition at $183.66 per share. 3,673,200
05/03/2021 Juan Andres
See remarks
5,000   Disposition at $183.66 per share. 918,300
05/03/2021 Tal Zaks
Chief Medical Officer
916   Disposition at $188 per share. 172,208
05/03/2021 Tal Zaks
Chief Medical Officer
1,924   Disposition at $187.1 per share. 359,980
05/03/2021 Tal Zaks
Chief Medical Officer
1,089   Disposition at $186.04 per share. 202,597
05/03/2021 Tal Zaks
Chief Medical Officer
800   Disposition at $184.77 per share. 147,816
05/03/2021 Tal Zaks
Chief Medical Officer
271   Disposition at $183.42 per share. 49,706
05/03/2021 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
05/03/2021 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
05/03/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
05/03/2021 Tal Zaks
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
100   Disposition at $183.74 per share. 18,374
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
800   Disposition at $182.84 per share. 146,272
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
4,845   Disposition at $182.05 per share. 882,032
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
1,400   Disposition at $180.41 per share. 252,574
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
1,809   Disposition at $179.45 per share. 324,625
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
1,792   Disposition at $178.35 per share. 319,603
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
300   Disposition at $175.27 per share. 52,581
04/29/2021 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $182.49 per share. 1,824,900
04/29/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $182.49 per share. 1,204,434
04/29/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
04/28/2021 Stéphane Bancel
Chief Executive Officer; Director
2,000   Gift at $0 per share. 0
04/28/2021 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $182.32 per share. 1,640,880
04/28/2021 Juan Andres
See remarks
5,000   Disposition at $182.32 per share. 911,600
04/28/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
04/27/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $178.29 per share. 1,176,714
04/27/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
04/26/2021 Stephen Hoge
President
5,000   Disposition at $171.77 per share. 858,850
04/26/2021 Juan Andres
See remarks
5,000   Disposition at $171.77 per share. 858,850
04/26/2021 Tal Zaks
Chief Medical Officer
100   Disposition at $179.37 per share. 17,937
04/26/2021 Tal Zaks
Chief Medical Officer
1,829   Disposition at $178.51 per share. 326,494
04/26/2021 Tal Zaks
Chief Medical Officer
900   Disposition at $177.41 per share. 159,669
04/26/2021 Tal Zaks
Chief Medical Officer
551   Disposition at $175.97 per share. 96,959
04/26/2021 Tal Zaks
Chief Medical Officer
400   Disposition at $175.03 per share. 70,012
04/26/2021 Tal Zaks
Chief Medical Officer
200   Disposition at $173.03 per share. 34,606
04/26/2021 Tal Zaks
Chief Medical Officer
1   Disposition at $171.65 per share. 171
04/26/2021 Tal Zaks
Chief Medical Officer
439   Disposition at $171.05 per share. 75,090
04/26/2021 Tal Zaks
Chief Medical Officer
580   Disposition at $169.87 per share. 98,524
04/26/2021 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
04/26/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
04/26/2021 Tal Zaks
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
04/23/2021 Stéphane Bancel
Chief Executive Officer; Director
100   Disposition at $175.32 per share. 17,532
04/23/2021 Stéphane Bancel
Chief Executive Officer; Director
4,985   Disposition at $174.13 per share. 868,038
04/23/2021 Stéphane Bancel
Chief Executive Officer; Director
3,500   Disposition at $173.17 per share. 606,095
04/23/2021 Stéphane Bancel
Chief Executive Officer; Director
1,300   Disposition at $172.22 per share. 223,886
04/23/2021 Stéphane Bancel
Chief Executive Officer; Director
661   Disposition at $171.13 per share. 113,116
04/23/2021 Stéphane Bancel
Chief Executive Officer; Director
500   Disposition at $169.17 per share. 84,585
04/23/2021 Stephen Hoge
President
100   Disposition at $175.34 per share. 17,534
04/23/2021 Stephen Hoge
President
1,400   Disposition at $174.46 per share. 244,244
04/23/2021 Stephen Hoge
President
4,639   Disposition at $173.81 per share. 806,304
04/23/2021 Stephen Hoge
President
2,200   Disposition at $172.81 per share. 380,182
04/23/2021 Stephen Hoge
President
1,000   Disposition at $171.77 per share. 171,770
04/23/2021 Stephen Hoge
President
5,100   Disposition at $170.18 per share. 867,918
04/23/2021 Stephen Hoge
President
561   Disposition at $169.18 per share. 94,909
04/23/2021 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
04/23/2021 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
/news/latest/company/us/mrna

MarketWatch News on MRNA

  1. Moderna Inc. stock underperforms Monday when compared to competitors

    4:31 p.m. May 10, 2021

    - MarketWatch Automation

  2. EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer.

    8:21 a.m. May 10, 2021

    - Josh Nathan-Kazis

  3. COVID-19 was never going to have a tidy Hollywood ending

    6:04 p.m. May 8, 2021

    - Quentin Fottrell

  4. Tussle Over Covid Vaccine Patents Looks Overblown

    7:40 p.m. May 7, 2021

    - Josh Nathan-Kazis

  5. Moderna Inc. stock outperforms competitors on strong trading day

    4:31 p.m. May 7, 2021

    - MarketWatch Automation

  6. Loading more headlines...
/news/nonmarketwatch/company/us/mrna

Other News on MRNA

  1. First Covid-19 Vaccine Cleared for U.S. Adolescents

    9:01 p.m. May 10, 2021

    - Jared S. Hopkins

  2. First Covid-19 Vaccine Cleared for U.S. Adolescents

    5:23 p.m. May 10, 2021

    - Jared S. Hopkins

  3. Biden's Budget May Boost These 3 Biotechs

    3:57 p.m. May 10, 2021

    - Motley Fool

  4. Moderna Could Be The Best Long-Term Hold In Biotech

    3:47 p.m. May 10, 2021

    - Seeking Alpha

  5. 7 Stocks Most at Risk of a Capital Gains Tax Selloff 

    1:08 p.m. May 10, 2021

    - InvestorPlace.com

  6. Novavax Faces Stormy Seas On Monday

    10:01 a.m. May 10, 2021

    - Seeking Alpha

  7. Are Coronavirus Vaccine Boosters Inevitable?

    9:35 a.m. May 10, 2021

    - Motley Fool

  8. CureVac Could Soon Join The Fight Against COVID-19

    5:43 a.m. May 10, 2021

    - Seeking Alpha

  9. Some Countries Shift Guidance on AstraZeneca Vaccine

    1:56 p.m. May 9, 2021

    - Kim Mackrael

  10. Should You Worry About This Threat to Moderna's Vaccine?

    6:00 a.m. May 9, 2021

    - Motley Fool

  11. Why Brooklyn ImmunoTherapeutics Stock Crushed It in April

    2:09 p.m. May 8, 2021

    - Motley Fool

  12. 4 Reasons to Hang On to Your Moderna Stock

    8:46 a.m. May 8, 2021

    - Motley Fool

  13. What's Going on With COVID Booster Shots?

    7:01 a.m. May 8, 2021

    - Motley Fool

  14. Moderna, Peloton, Microsoft: Stocks That Defined the Week

    6:44 p.m. May 7, 2021

    - Francesca Fontana

  15. Loading more headlines...

At a Glance

Moderna, Inc.

200 Technology Square

Cambridge, Massachusetts 02139

Phone

1 6177146500

Industry

-

Sector

-

Fiscal Year-end

12/2021

Revenue

$803.40M

Net Income

$-747.06M

2020 Sales Growth

1234.3%

Employees

1,300

/news/pressrelease/company/us/mrna

Press Releases on MRNA

  1. Nasdaq 100 Movers: CTSH, FOXA

    10:47 a.m. May 6, 2021

    - MarketNewsVideo.com

  2. Nasdaq 100 Movers: CTSH, FOXA

    10:44 a.m. May 6, 2021

    - MarketNewsVideo.com

  3. Moderna Plunges on Numbers, Vaccine Effectiveness

    10:13 a.m. May 6, 2021

    - Baystreet.ca

  4. Moderna, Inc. to Host Earnings Call

    6:15 a.m. May 6, 2021

    - ACCESSWIRE

  5. Vaxart Up on New Test Data

    10:12 a.m. May 4, 2021

    - Baystreet.ca

  6. 4 Top Biotech Stocks To Watch In May 2021

    9:50 p.m. May 3, 2021

    - StockMarket.com

  7. Nasdaq 100 Movers: SWKS, MRNA

    11:56 a.m. May 3, 2021

    - MarketNewsVideo.com

  8. How to Develop Investment Plans for Moderna Inc. Common Stock #MRNA

    10:33 p.m. April 30, 2021

    - Stock Traders Daily

  9. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.